$722 Million is the total value of GREAT POINT PARTNERS LLC's 44 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ONCE | Sell | SPARK THERAPEUTICS INC | $41,380,000 | -99.9% | 500,000 | -9.1% | 5.74% | +5.4% |
| NVCR | Sell | NOVOCURE LTD | $22,348,000 | -99.9% | 713,998 | -5.2% | 3.10% | +27.0% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $13,167,000 | -100.0% | 302,000 | -76.9% | 1.82% | -76.2% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $9,644,000 | -100.0% | 3,407,840 | -60.3% | 1.34% | -70.4% |
| ACHN | Sell | ACHILLION PHARMACEUTICALS INC | $8,458,000 | -99.9% | 2,988,716 | -19.2% | 1.17% | -42.5% |
| CTIC | Sell | CTI BIOPHARMA CORP | $7,654,000 | -99.9% | 1,537,020 | -8.9% | 1.06% | +8.6% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $6,752,000 | -99.9% | 2,280,921 | -26.7% | 0.94% | -2.1% |
| ARNA | Exit | ARENA PHARMACEUTICALS INCcall | $0 | – | -15,300 | -100.0% | -0.09% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -500,000 | -100.0% | -0.16% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -233,500 | -100.0% | -0.25% | – |
| MNLO | Exit | MENLO THERAPEUTICS INC | $0 | – | -52,008 | -100.0% | -0.29% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INCput | $0 | – | -200,000 | -100.0% | -0.70% | – |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -309,800 | -100.0% | -0.78% | – |
| PTCT | Exit | PTC THERAPEUTICS INCcall | $0 | – | -200,000 | -100.0% | -0.80% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -2,695,742 | -100.0% | -0.96% | – |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -1,491,500 | -100.0% | -2.01% | – |
| PRTA | Exit | PROTHENA CORP PLCcall | $0 | – | -500,000 | -100.0% | -2.73% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -900,579 | -100.0% | -4.26% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -400,000 | -100.0% | -4.93% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -500,000 | -100.0% | -5.05% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -978,302 | -100.0% | -5.82% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| CYTOKINETICS INC | 18 | Q2 2024 | 7.1% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Context Therapeutics Inc. | June 05, 2024 | 7,419,355 | 9.9% |
| Outlook Therapeutics, Inc. | April 08, 2024 | 2,231,324 | 10.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 3,703,433 | 6.4% |
| Avalo Therapeutics, Inc. | February 14, 2024 | 2,085 | 0.3% |
| HERON THERAPEUTICS, INC. /DE/Sold out | February 14, 2024 | 0 | 0.0% |
| Neurogene Inc. | February 14, 2024 | 994,229 | 7.8% |
| OptiNose, Inc. | February 14, 2024 | 11,484,120 | 10.0% |
| PRECISION BIOSCIENCES INCSold out | February 14, 2024 | 0 | 0.0% |
| UroGen Pharma Ltd. | February 14, 2024 | 2,620,545 | 8.5% |
| Vistagen Therapeutics, Inc. | February 14, 2024 | 2,792,927 | 10.0% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| SC 13G | 2024-08-15 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-08-05 |
| SC 13G | 2024-07-18 |
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.